Xilio Therapeutics

Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.

Xilio Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Biopharma, Therapeutics, Oncology sector. The company focuses on Biotechnology and has secured $24.4B in funding across 100 round(s). With a team of 51-100 employees, Xilio Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Xilio Therapeutics, raised $7.5M. Discover more about their projects, partnerships, and impact on our platform.